Elizabeth Plimack
#151,490
Most Influential Person Now
American medical oncologist
Elizabeth Plimack's AcademicInfluence.com Rankings
Elizabeth Plimackphilosophy Degrees
Philosophy
#9475
World Rank
#13040
Historical Rank
Logic
#6448
World Rank
#7965
Historical Rank
Download Badge
Philosophy
Elizabeth Plimack's Degrees
- Doctorate Medicine University of Pennsylvania
- Masters Clinical Epidemiology University of Pennsylvania
Why Is Elizabeth Plimack Influential?
(Suggest an Edit or Addition)According to Wikipedia, Elizabeth R. Plimack is an American medical oncologist. She is a professor in the Department of Hematology/Oncology and Chief of the Division of Genitourinary Medical Oncology at the Fox Chase Cancer Center. In these roles, she researches the treatment of genitourinary malignancies with a focus on bladder and kidney cancers.
Elizabeth Plimack's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. (2015) (4550)
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma (2018) (2700)
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma (2019) (1808)
- Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. (2014) (1297)
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy (2018) (1272)
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. (2017) (1243)
- Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. (2019) (1026)
- NCCN clinical practice guidelines in oncology: prostate cancer. (2010) (971)
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. (2015) (926)
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. (2017) (880)
- Prostate Cancer, Version 1.2016. (2016) (586)
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. (2018) (546)
- Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. (2017) (474)
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. (2019) (473)
- Featured Updates to the NCCN Guidelines (2019) (401)
- Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. (2015) (360)
- Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. (2012) (358)
- Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. (2017) (334)
- Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. (2017) (307)
- Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. (2020) (297)
- Prostate Cancer,,Version 2.2014 Clinical Practice Guidelines in Oncology (2014) (277)
- Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. (2020) (276)
- Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. (2018) (273)
- Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). (2014) (253)
- Prostate cancer, version 2.2014. (2014) (252)
- Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial (2020) (234)
- Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. (2017) (230)
- Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. (2014) (224)
- Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. (2017) (213)
- Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma (2016) (208)
- CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. (2017) (201)
- Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. (2017) (200)
- Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. (2016) (188)
- Kidney cancer, version 3.2015: Featured updates to the NCCN guidelines (2015) (186)
- NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. (2018) (180)
- Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. (2016) (176)
- Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). (2014) (171)
- Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial. (2016) (156)
- A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. (2012) (144)
- Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study (2018) (141)
- Penile cancer: Clinical Practice Guidelines in Oncology. (2013) (139)
- Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. (2020) (134)
- Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial (2020) (130)
- Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. (2012) (129)
- PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection (2013) (129)
- Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer. (2017) (124)
- Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012. (2015) (123)
- NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. (2019) (122)
- Kidney cancer, version 3.2015. (2015) (119)
- Lymphopenia is an independent predictor of inferior outcome in clear cell renal carcinoma. (2013) (112)
- Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. (2020) (112)
- Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors. (2017) (111)
- Prostate cancer, version 1.2014. (2013) (108)
- Decitabine and its role in the treatment of hematopoietic malignancies (2007) (106)
- EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma (2020) (103)
- Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. (2019) (102)
- AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors. (2013) (100)
- Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis (2021) (97)
- Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. (2022) (96)
- CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups (2017) (90)
- Testicular cancer, version 2.2015: Clinical pactice guidelines in oncology (2015) (88)
- Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma (2019) (85)
- Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer (2017) (84)
- ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer (2018) (83)
- Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study. (2019) (82)
- NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. (2020) (80)
- Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. (2019) (80)
- A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma. (2015) (75)
- Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). (2015) (75)
- Kidney cancer, version 2.2014. (2014) (73)
- Testicular Cancer, Version 2.2015. (2015) (69)
- Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With Cancer. (2016) (68)
- Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy. (2011) (67)
- Bladder cancer. (2013) (67)
- Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. (2017) (66)
- Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial. (2014) (66)
- NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. (2016) (64)
- Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial. (2014) (63)
- Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study (2016) (62)
- Bladder Cancer, Version 2.2016 Featured Updates to the NCCN Guidelines (2016) (61)
- Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. (2018) (60)
- Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC). (2017) (59)
- Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma. (2016) (57)
- LBA23A PHASE 1B STUDY OF PEMBROLIZUMAB (PEMBRO; MK-3475) IN PATIENTS (PTS) WITH ADVANCED UROTHELIAL TRACT CANCER (2014) (56)
- Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population. (2017) (55)
- Kidney cancer, version 1.2021: Featured updates to the nccn guidelines (2020) (55)
- Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study (2017) (53)
- Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426. (2021) (52)
- A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157 (2016) (51)
- Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). (2020) (51)
- Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy (2011) (50)
- Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies. (2016) (50)
- Approved checkpoint inhibitors in bladder cancer: which drug should be used when? (2018) (49)
- CheckMate 214: A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma. (2015) (48)
- Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma. (2019) (48)
- Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma (2017) (46)
- Coexisting hybrid malignancy in a solitary sporadic solid benign renal mass: implications for treating patients following renal biopsy. (2014) (46)
- Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426. (2020) (46)
- Micropapillary bladder cancer: current treatment patterns and review of the literature. (2014) (46)
- Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors (2015) (44)
- Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma (2022) (44)
- Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions (2018) (43)
- Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC). (2018) (43)
- Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors (2014) (43)
- Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. (2020) (42)
- Emerging role of immunotherapy in urothelial carcinoma-Advanced disease. (2016) (39)
- Muscle-invasive urothelial bladder cancer: an update on systemic therapy (2015) (38)
- Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260). (2020) (38)
- CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC). (2016) (37)
- Pembrolizumab (Pembro; MK-3475) for advanced urothelial cancer: Results of a phase IB study. (2015) (36)
- Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis. (2018) (35)
- Targeting Signaling Transduction Pathways in Bladder Cancer (2015) (34)
- Bladder cancer, version 3.2020 (2020) (34)
- Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle‐invasive bladder cancer (2019) (34)
- Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC). (2018) (33)
- Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results (2016) (32)
- Distress and Financial Distress in Adults With Cancer: An Age-Based Analysis. (2017) (32)
- Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107 (2017) (31)
- Recent developments in the treatment of advanced bladder cancer. (2018) (31)
- Hypoalbuminaemia is associated with mortality in patients undergoing cytoreductive nephrectomy (2015) (31)
- Sunitinib in papillary renal cell carcinoma (pRCC): Results from a single-arm phase II study. (2010) (31)
- Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma (2015) (30)
- Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon (2009) (30)
- Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma. (2018) (30)
- Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes. (2015) (29)
- Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial. (2018) (29)
- Combining epigenetic and cytotoxic therapy in the treatment of solid tumors. (2007) (28)
- Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: Results from the phase II CheckMate 275 study (2016) (27)
- Phase I/II study of the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC). (2020) (27)
- Sunitinib in non-clear cell renal cell carcinoma (ncc-RCC): A phase II study (2008) (26)
- LBA26 PHASE II TRIAL OF NEOADJUVANT CHEMOTHERAPY FOLLOWED BY EXTIRPATIVE SURGERY FOR PATIENTS WITH HIGH GRADE UPPER TRACT UROTHELIAL CARCINOMA (HG UTUC): RESULTS FROM ECOG-ACRIN 8141 (2018) (26)
- Neoadjuvant dose-dense gemcitabine and cisplatin (DDGC) in patients (pts) with muscle-invasive bladder cancer (MIBC): Final results of a multicenter phase II study. (2014) (26)
- Evaluating toxicity from definitive radiation therapy for prostate cancer in men with inflammatory bowel disease: Patient selection and dosimetric parameters with modern treatment techniques. (2015) (25)
- Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma (2015) (25)
- Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status (2020) (24)
- First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer. (2019) (24)
- Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials. (2014) (24)
- A phase II trial of risk enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN BLADDER): Interim analysis. (2021) (24)
- 661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC) (2021) (24)
- Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC). (2020) (23)
- Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study. (2016) (23)
- 1052PDNIVOLUMAB (N) (ANTI-PD-1; BMS-936558, ONO-4538) IN COMBINATION WITH SUNITINIB (S) OR PAZOPANIB (P) IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC). (2014) (23)
- A phase I study of temsirolimus and bryostatin-1 in patients with metastatic renal cell carcinoma and soft tissue sarcoma. (2014) (22)
- Role of Checkpoint Inhibition in Localized Bladder Cancer. (2018) (22)
- KEYNOTE-052: Phase 2 study evaluating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)— Updated response and survival results. (2019) (22)
- Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma (2018) (22)
- NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. (2022) (22)
- Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies. (2019) (21)
- The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma (2016) (20)
- Mature results from EV-101: A phase I study of enfortumab vedotin in patients with metastatic urothelial cancer (mUC). (2019) (20)
- 711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy (2020) (19)
- Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database (2018) (19)
- Optimizing systemic therapy for bladder cancer. (2013) (19)
- Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance) (2021) (18)
- A phase I study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in combination with sunitinib, pazopanib, or ipilimumab in patients (pts) with metastatic renal cell carcinoma (mRCC). (2013) (18)
- Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy. (2020) (18)
- First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. (2021) (18)
- 1050OPHASE I STUDY OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN METASTATIC RENAL CELL CARCINOMA (MRCC). (2014) (18)
- First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study. (2021) (17)
- The oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC): Updated follow-up of a phase I/II study. (2021) (17)
- Defining “platinum-ineligible” patients with metastatic urothelial cancer (mUC). (2019) (16)
- Updated results from a phase I study of nivolumab (Nivo) in combination with ipilimumab (Ipi) in metastatic renal cell carcinoma (mRCC): The CheckMate 016 study (2016) (16)
- Clinical implications of molecular subtyping in bladder cancer. (2019) (16)
- Mutational load (ML) and T-cell-inflamed microenvironment as predictors of response to pembrolizumab. (2017) (16)
- A prospective observational study of metastatic renal cell carcinoma (mRCC) prior to initiation of systemic therapy. (2014) (15)
- A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma (2019) (15)
- Phase 2 trial results of DN24-02, a HER2-targeted autologous cellular immunotherapy in HER2+ urothelial cancer patients (pts). (2016) (14)
- SWOG 1107: Parallel (randomized) phase II evaluation of tivantinib (ARQ-197) and tivantinib in combination with erlotinib in patients (Pts) with papillary renal cell carcinoma (pRCC). (2015) (14)
- KEYNOTE-045: Randomized phase 3 trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer. (2015) (14)
- Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC). (2015) (14)
- Results from a phase I expansion cohort of the first-in-class oral HIF-2α inhibitor PT2385 in combination with nivolumab in patients with previously treated advanced RCC. (2019) (13)
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer (2021) (13)
- Potential role of 124I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer (2012) (13)
- Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect. (2019) (13)
- Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials. (2019) (13)
- Molecular and Clinical Insights into the Role and Significance of Mutated DNA Repair Genes in Bladder Cancer (2018) (13)
- Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial (2021) (13)
- A first-in-human phase I/II trial of the oral HIF-2a inhibitor PT2977 in patients with advanced RCC (2019) (12)
- KEYNOTE-905/EV-303: Perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) and cystectomy compared to cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC). (2021) (12)
- Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214. (2019) (12)
- Neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) in patients with high-grade upper-tract urothelial carcinoma. (2014) (12)
- Abstract CT178: Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update and association between biomarkers and overall survival in CheckMate 275 (2018) (12)
- Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population (2018) (12)
- Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update from CheckMate 275. (2019) (12)
- Safety and efficacy of axitinib (axi) in combination with pembrolizumab (pembro) in patients (pts) with advanced renal cell cancer (aRCC). (2018) (12)
- Defects in DNA repair genes and sensitivity to cisplatin based neoadjuvant chemotherapy (NAC) for bladder cancer. (2015) (12)
- Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study. (2019) (12)
- Small‐Cell Carcinoma of the Bladder: 20‐Year Single‐Institution Retrospective Review (2017) (12)
- Integrating Immunotherapy Into the Management of Renal Cell Carcinoma. (2017) (11)
- Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A) (2022) (11)
- Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial. (2021) (11)
- Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder Cancer. (2019) (11)
- A phase I study of decitabine with pegylated interferon α-2b in advanced melanoma: impact on DNA methylation and lymphocyte populations (2014) (11)
- CheckMate 025: a randomized, open-label, phase Ill study of nivolumab versus everolimus in advanced renal cell carcinoma (RCC) (2015) (11)
- Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group. (2004) (11)
- National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer. (2016) (11)
- Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer (2020) (11)
- Cystoscopy and Systematic Bladder Tissue Sampling in Predicting pT0 Bladder Cancer: A Prospective Trial. (2021) (10)
- Integration of Immunotherapy Into the Treatment of Advanced Urothelial Carcinoma. (2020) (10)
- Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based Approach. (2015) (10)
- Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study. (2006) (10)
- A single-arm biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer (PRCC). (2017) (10)
- NeuACT, a phase II, randomized, open-label trial of DN24-02: Updated analysis of HER2 expression, immune responses, product parameters, and safety in patients with surgically resected HER2+ urothelial cancer. (2014) (10)
- KEYNOTE-052: Phase 2 study of pembrolizumab (MK-3475) as first-line therapy for patients (pts) with unresectable or metastatic urothelial cancer ineligible for cisplatin-based therapy. (2015) (10)
- Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers. (2020) (10)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial. (2021) (10)
- Outcome of patients (pts) with renal medullary carcinoma (RMC) treated in the era of targeted therapies (TT): A multicenter experience. (2011) (10)
- The European Urology Commitment to Gender Equity and Diversity: Expanding Cognitive Diversity through Inclusivity at the Podium. (2021) (9)
- Phase 3, randomized, double-blind trial of pembrolizumab plus epacadostat or placebo for cisplatin-ineligible urothelial carcinoma (UC): KEYNOTE-672/ECHO-307. (2018) (9)
- The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer. (2019) (9)
- Provider and patient burdens of obtaining oral anticancer medications. (2018) (9)
- Role of immunotherapy in localized muscle invasive urothelial cancer (2021) (9)
- Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle‐Invasive Bladder Cancer (2019) (9)
- Circulating biomarkers to guide systemic therapy for urothelial carcinoma. (2016) (9)
- Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial. (2020) (9)
- Molecular Profiling of Exceptional Responders to Cancer Therapy. (2020) (9)
- Systemic therapy for bladder cancer finally comes into a new age. (2016) (8)
- Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma (2020) (8)
- A phase II trial of risk-adapted treatment for muscle invasive bladder cancer after neoadjuvant accelerated MVAC. (2018) (8)
- Targeted Therapy for Metastatic Urothelial Cancer: A Work in Progress. (2016) (8)
- TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy (2016) (8)
- Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma. (2022) (8)
- Selecting targeted therapies for patients with renal cell carcinoma. (2011) (8)
- Correction to: Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma (2019) (8)
- A review of interventional clinical trials in renal cell carcinoma: a status report from the ClinicalTrials.gov WebSite. (2015) (7)
- Evolving landscape of the treatment of metastatic clear cell renal cell carcinoma. (2018) (7)
- Preliminary product parameter and safety results from NeuACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer at high risk for recurrence. (2014) (7)
- Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results From the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. (2022) (7)
- Outcomes for patients in the pembrolizumab+axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study. (2021) (7)
- Assessing Contemporary Trends in Female Speakership within Urologic Oncology. (2020) (7)
- 1051PDIMMUNOMODULATORY ACTIVITY OF NIVOLUMAB IN PREVIOUSLY TREATED AND UNTREATED METASTATIC RENAL CELL CARCINOMA (MRCC): BIOMARKER-BASED RESULTS FROM A RANDOMIZED CLINICAL TRIAL. (2014) (7)
- Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions. (2016) (7)
- ECOG 8141: A prospective phase II trial of neoadjuvant systemic chemotherapy followed by extirpative surgery for patients with high grade upper tract urothelial carcinoma. (2016) (7)
- Correlation of response with overall survival (OS) for nivolumab vs everolimus in advanced renal cell carcinoma (aRCC): Results from the phase III CheckMate 025 study. (2016) (7)
- Second-generation Androgen Receptor-targeted Therapies in Nonmetastatic Castration-resistant Prostate Cancer: Effective Early Intervention or Intervening Too Early? (2016) (6)
- Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop (2021) (6)
- A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1) (2022) (6)
- Next-generation sequencing to identify molecular alterations in DNA repair and chromatin maintenance genes associated with pathologic complete response (pT0) to neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) in muscle-invasive bladder cancer (MIBC). (2014) (6)
- Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney Cancer. (2019) (6)
- Effect of EGFR inhibition with cetuximab on the efficacy of paclitaxel in previously treated metastatic urothelial cancer. (2011) (6)
- Effect of EGFR inhibition with cetuximab (CET) on the efficacy of paclitaxel (TAX) in previously treated metastatic (MET) urothelial cancer. (2011) (6)
- Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma. (2021) (6)
- ECOG 1808: Randomized phase II trial of sunitinib with or without gemcitabine in advanced kidney cancer with sarcomatoid features. (2016) (6)
- Biomarkers for neoadjuvant checkpoint blockade response in urothelial cancer (2019) (6)
- Enfortumab vedotin (EV) in patients (Pts) with metastatic urothelial carcinoma (mUC) with prior checkpoint inhibitor (CPI) failure: A prospective cohort of an ongoing phase 1 study. (2018) (5)
- Corticosteroids and prostate cancer: friend or foe? (2015) (5)
- Erratum to "CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma" [Eur Urol 2017;72:962-71]. (2018) (5)
- Neoadjuvant accelerated MVAC (AMVAC) in patients with muscle invasive bladder cancer: Results of a multicenter phase II study. (2012) (5)
- 810ORANDOMIZED, DOSE-RANGING PHASE II TRIAL OF NIVOLUMAB FOR METASTATIC RENAL CELL CARCINOMA (MRCC). (2014) (5)
- The DART Study: Part 1 results from the dalantercept plus axitinib dose escalation and expansion cohorts in patients with advanced renal cell carcinoma (RCC). (2015) (5)
- HER2 expression in patients (pts) with surgically resected urothelial cancer at high risk of recurrence screened for the phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2. (2013) (5)
- Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma (2022) (5)
- MP68-11 A PHASE 1B STUDY OF PEMBROLIZUMAB (PEMBRO; MK-3475) FOR ADVANCED UROTHELIAL CANCER (2015) (5)
- Clinical Stage T1 micropapillary urothelial carcinoma presenting with metastasis to the pancreas. (2012) (5)
- Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer. (2016) (5)
- Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced clear cell renal cell (HCRN GU16-260-Cohort A): Final report. (2022) (5)
- Efficacy and safety of endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors (TKI) after programmed cell death 1 (PD-1) inhibitor treatment in patients with metastatic clear cell renal cell carcinoma (mccRCC). (2015) (5)
- 857PPembrolizumab (pembro) as first-line therapy in cisplatin-ineligible advanced urothelial cancer (UC): Outcomes from KEYNOTE-052 in senior patients (pts) with poor performance status (2017) (5)
- Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study (2019) (4)
- A phase II study of pazopanib (P) in patients (Pts) with localized renal cell carcinoma (RCC) to enable partial nephrectomy (PN). (2014) (4)
- Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214. (2021) (4)
- THE 2017 AMERICAN JOINT COMMITTEE ON CANCER EIGHTH EDITION CANCER STAGING MANUAL: CHANGES IN STAGING GUIDELINES FOR CANCERS OF THE KIDNEY, RENAL PELVIS AND URETER, BLADDER, AND URETHRA: MP86‐17 (2017) (4)
- A phase Ib multicohort study of MK-3475 in patients with advanced solid tumors. (2014) (4)
- 501 Efficacy and safety of nivolumab in patients with metastatic renal cell carcinoma who were treated beyond progression in a randomized phase 2 dose-ranging trial (2015) (4)
- Genomic biomarkers in relation to PD-1 checkpoint blockade response. (2018) (4)
- 3LBA CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC) (2015) (4)
- Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors (2017) (4)
- 747P Association of TMB with efficacy of pembrolizumab (pembro) in patients (pts) with advanced urothelial cancer (UC): Results from KEYNOTE-045 and KEYNOTE-052 (2020) (4)
- A wealth of new options: a case presentation of the management of castration-recurrent prostate cancer. (2012) (4)
- Systemic Therapy for Advanced Non-clear-Cell Renal Cell Carcinoma: Slow but Definite Progress. (2021) (4)
- Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced non-clear cell renal cell carcinoma (nccRCC) (HCRN GU16-260-Cohort B). (2021) (4)
- Phase III study of perioperative pembrolizumab (pembro) plus cystectomy versus cystectomy alone in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-905. (2020) (3)
- Molecular profiling of aggressive variant urothelial carcinoma. (2019) (3)
- Health-related quality of life as a marker of treatment benefit with nivolumab in platinum-refractory patients with metastatic or unresectable urothelial carcinoma from CheckMate 275. (2017) (3)
- Checkpoint Inhibitors and Urothelial Carcinoma: The Translational Paradigm. (2016) (3)
- Real-world outcomes in patients with metastatic clear cell renal cell carcinoma receiving front-line axitinib plus pembrolizumab versus ipilimumab plus nivolumab. (2021) (3)
- PD66-06 PROSPECTIVE EVALUATION OF CYSTOSCOPY AND BLADDER MAPPING REVEALS NEARLY A 30% MISS RATE FOR ≥PT2 PATHOLOGY (2019) (3)
- A phase 1b/2 umbrella study of investigational immune and targeted combination therapies as first-line therapy for patients with advanced renal cell carcinoma (RCC). (2021) (3)
- Safety and Efficacy of Nivolumab in PatientsWithMetastatic Renal Cell Carcinoma Treated Beyond Progression (2016) (3)
- Abstract 3141: Immune gene expression and prognosis in localized clear cell (cc) renal cell carcinoma (RCC) (2018) (3)
- Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus (SAGE): Results of a Phase II Trial. (2020) (3)
- A two-part phase 2 randomized study of dalantercept and axitinib versus placebo plus axitinib in advanced renal cell carcinoma: Results from the part 1 dose escalation cohorts. (2014) (3)
- Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial. (2022) (3)
- Preliminary HER2 expression data from NeuACT, the phase II randomized, open-label trial of DN24-02 in patients (pts) with surgically resected HER2+ urothelial cancer (UC) at high risk for recurrence. (2013) (3)
- Human capital costs of obtaining oral anticancer medications. (2016) (3)
- Pembrolizumab produces clinically meaningful responses as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from subgroup analyses of KEYNOTE-052 (2017) (3)
- Patterns of PSA versus clinically progressive disease in the E3805 CHAARTED trial. (2018) (3)
- 669P Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study (2021) (2)
- Association of eosinophila with efficacy in non-melanoma patients treated with programmed death 1 inhibitors. (2016) (2)
- Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival. (2019) (2)
- Impact of number of cycles of platinum-based first-line chemotherapy for advanced urothelial carcinoma. (2018) (2)
- Bladder Cancer , Version 5 . 2017 Clinical Practice Guidelines in Oncology (2017) (2)
- Renal Pelvis and Ureter (2017) (2)
- Relationships among financial distress, emotional symptoms, and overall distress in insured cancer patients. (2014) (2)
- The use of radiation for stage I seminoma: Analysis of the National Cancer Database. (2015) (2)
- A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study. (2023) (2)
- Measuring the Efficacy and Value of Urothelial Cancer Urinary Biomarkers (2015) (2)
- Non-urothelial bladder cancer: Genomic alterations and patient outcomes. (2019) (2)
- First-line Immunotherapy in Metastatic Urothelial Carcinoma. (2020) (2)
- CLINICAL DESTINY OF INDETERMINATE PULMONARY NODULES IN PATIENTS UNDERGOING RADICAL CYSTECTOMY FOR UROTHELIAL CARCINOMA OF THE BLADDER: MP58‐12 (2017) (2)
- Effect of exogenous interferon-gamma (IFN-gamma) on peripheral blood immune markers as part of a phase I clinical trial of combined IFN-gamma with nivolumab (Nivo) in patients (pts) with select solid tumors. (2017) (2)
- A Seat at the Table: The Correlation Between Female Authorship and Urology Journal Editorial Board Membership. (2022) (2)
- Treatment of Metastatic Urothelial Carcinoma After Previous Cisplatin-based Chemotherapy for Localized Disease: A Retrospective Comparison of Different Chemotherapy Regimens. (2020) (2)
- An observational study of metastatic renal cell carcinoma patients prior to initiation of initial systemic therapy. (2012) (2)
- Phase 2 trial of dovitinib in Bacillus Calmette-Guerin (BCG) refractory urothelial carcinoma (UC) with tumor FGFR3 mutations or over-expression: Hoosier Cancer Research Network GU12-157. (2016) (2)
- DART Study: A phase II randomized trial of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma (RCC): Results from Part 1. (2015) (2)
- Patterns of progression in renal cell carcinoma: antivascular therapy compared with interferon (2008) (2)
- A phase I study of temsirolimus (TEM) and bryostatin (BRYO) in patients with metastatic renal cell carcinoma (RCC). (2016) (2)
- Axitinib plus pembrolizumab in patients with advanced renal cell carcinoma: Long-term efficacy and safety from a phase Ib study. (2020) (2)
- Kidney Cancer, Version 3.2022 (2021) (2)
- Safety, pharmacokinetics, and antitumor activity of MEDI-573, an investigational monoclonal antibody that targets IGF-I and IGF-II, in adult patients with advanced solid tumors. (2012) (2)
- 417 Phase 3 study of pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib as first-line treatment for advanced renal cell carcinoma (2021) (2)
- Abstract 4298: Defects in DNA repair genes and sensitivity to cisplatin based neoadjuvant chemotherapy (NAC) for bladder cancer (2015) (2)
- Prolonged natural progression from localized to symptomatic renal cell carcinoma. (2012) (2)
- Molecular profiling of cancer outliers. (2017) (2)
- Clinical destiny of indeterminate pulmonary nodules in patients undergoing radical cystectomy for urothelial carcinoma of the bladder. (2017) (2)
- Phase 3 study of first-line treatment with pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib for advanced renal cell carcinoma (RCC). (2022) (1)
- 875POutcomes of patients with metastatic urothelial carcinoma (mUC) with exclusive bone metastases: Focus on a special patient population (2017) (1)
- A phase I/II study of nivolumab and axitinib in patients with advanced renal cell carcinoma. (2022) (1)
- Association between baseline body mass index and survival in men with metastatic hormone‐sensitive prostate cancer: ECOG‐ACRIN CHAARTED E3805 (2022) (1)
- KEYNOTE-905: A phase III study of cystectomy plus perioperative pembrolizumab versus cystectomy alone in cisplatin (cis)-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC) (2019) (1)
- NCCN Prostate Cancer , Version 2 . 2014 Clinical Practice Guidelines in Oncology (2014) (1)
- Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who receive second-line immunotherapy. (2021) (1)
- THE EFFECT OF INTRINSIC SUBTYPE ON RESPONSE TO NEOADJUVANT CHEMOTHERAPY FOR MUSCLE INVASIVE BLADDER CANCER: PD62‐03 (2017) (1)
- Subclonal mutational heterogeneity and survival in cisplatin-resistant muscle-invasive bladder cancer. (2017) (1)
- 717TiP Randomized, open-label, 3-arm phase III study comparing MK-1308A + lenvatinib and pembrolizumab (pembro) + belzutifan + lenvatinib versus pembro + lenvatinib as first-line (1L) treatment for advanced clear cell renal cell carcinoma (ccRCC) (2021) (1)
- LBA5 INITIAL RESULTS OF A PROSPECTIVE COHORT STUDY EVALUATING RELIABILITY OF ENDOSCOPIC EVALUATION IN PREDICTING PT0 DISEASE AT THE TIME OF RADICAL CYSTECTOMY: WHERE AND HOW DOES CYSTOSCOPY FALL SHORT? (2018) (1)
- Overcoming mTOR resistance: Results of a phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat. (2014) (1)
- Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab (2015) (1)
- MP61-07 IDENTIFICATION OF DISTINCT BASAL AND LUMINAL SUBSETS OF HUMAN BLADDER CANCERS WITH DIFFERENT SENSITIVITIES TO FRONTLINE CHEMOTHERAPY (2014) (1)
- Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. (2022) (1)
- A phase II study of alternative sunitinib scheduling in patients with metastatic renal cell carcinoma. (2017) (1)
- What’s in a Name: An Analysis of Gender-Based Acronyms in Clinical Trials (2023) (1)
- Defects in DNA repair genes and long-term survival in cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer (MIBC). (2019) (1)
- Immune related adverse events as a biomarker in non-melanoma patients treated with programmed death 1 inhibitors (PD-1Is). (2016) (1)
- Pembrolizumab plus ipilimumab or pegylated interferon alfa-2b for patients with melanoma or renal cell carcinoma: take new drugs but keep the old? (2019) (1)
- A new 50-gene molecular subtype classifier: An evaluation of subtype stability and association with response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. (2018) (1)
- The DART Study: A phase 2 randomized double-blind study of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma (RCC). (2015) (1)
- Comparative cost‐effectiveness of neoadjuvant chemotherapy regimens for muscle‐invasive bladder cancer: Results according to VESPER data (2022) (1)
- Phase II study of alternate sunitinib schedule in patients with metastatic renal cell carinoma. (2017) (1)
- Phase I/II study of axitinib (axi) and nivolumab (nivo) in patients with metastatic renal cell carcinoma (mRCC). (2019) (1)
- Squamous-cell carcinoma variant histology (SCC-VH) in muscle-invasive bladder cancer (MIBC): A comprehensive clinical, genomic, and therapeutic assessment from multiple datasets. (2019) (1)
- Immunotherapy for metastatic urothelial carcinoma: putting the brakes on releasing the brake. (2018) (1)
- Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer (2022) (1)
- Clinical evaluation of cisplatin sensitivity germ line polymorphisms in neoadjuvant chemotherapy (NAC) for urothelial cancer (UC). (2014) (1)
- Genomic evolution in muscle-invasive bladder cancer resistant to neoadjuvant chemotherapy. (2016) (1)
- Researchers The NCCN Prostate Cancer Clinical Practice Guidelines in OncologyTM (2010) (1)
- Mechanisms of immunotherapy resistance in mCRPC: identifying the enemy on the visceral metastatic battlefield. (2014) (1)
- Abstract 548: Urine biopsy as dynamic marker to enhance clinical staging of urothelial carcinoma (2021) (1)
- Abstract 995: Impact of molecular subtypes on predicting chemotherapy response and survival in muscle invasive bladder cancer (2017) (1)
- Management and outcomes of patients with renal medullary carcinoma (RMC): A multicenter retrospective study of 39 patients. (2015) (1)
- Pembrolizumab (pembro) as first-line therapy in elderly patients (pts) with poor performance status with cisplatin-ineligible advanced urothelial cancer (UC): Results from Keynote-052 (2018) (1)
- PD-1 expression on classical monocytes (CM) as an independent predictor of cancer specific survival in clear cell renal carcinoma (ccRCC). (2016) (0)
- 522 NEOADJUVANT ACCELERATED MVAC IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER: A MULTI-INSTITUTIONAL PROSPECTIVELY ACCRUED COHORT (2013) (0)
- Phase 3 KEYNOTE-905/EV-303: Perioperative pembrolizumab (pembro) or pembro + enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC). (2023) (0)
- Abstract B14: Neoantigen burden associates with chemoresponse in muscle-invasive bladder cancer patients receiving neoadjuvant chemotherapy (2017) (0)
- MP39-13 COST-EFFECTIVENESS OF NEOADJUVANT CHEMOTHERAPY REGIMENS PRIOR TO RADICAL CYSTECTOMY FOR MUSCLE-INVASIVE BLADDER CANCER (2022) (0)
- Management and outcomes of patients with renal medullary carcinoma (RMC): A collaborative multi-center study of 52 patients. (2016) (0)
- Abstract CT121: A Phase II trial of guadecitabine (G) plus atezolizumab (A) in patients with metastatic urothelial carcinoma (UC) progressing after initial checkpoint inhibitor therapy (2021) (0)
- Nomogram-based risk prediction of local and distant relapse after radical cystectomy, and role of perioperative chemotherapy, in patients with muscle-invasive bladder cancer (MIBC): A multicenter study (2018) (0)
- Predictive impact of intrinsic bladder cancer subtypes on survival after radical cystectomy (2017) (0)
- Nomogram-based risk prediction of local and distant relapse after radical cystectomy, and role of perioperative chemotherapy, in patients with muscle-invasive bladder cancer (MIBC): A multicenter study. (2018) (0)
- 910PExome sequencing of tumor samples from S1107 “Randomized phase II evaluation of tivantinib and tivantinib in combination with erlotinib in patients with papillary renal cell carcinoma (pRCC)” (2017) (0)
- Examination of resistance to nivolumab monotherapy through single-cell analysis of tumors from patients enrolled in the HCRN GU16-260 study of nivolumab monotherapy. (2023) (0)
- Genomic and immunologic profiles of concurrent RB1 and CDKN1A/p21(WAF1) truncating mutations (RW+) in bladder cancer. (2022) (0)
- PD12-07 DECLINE IN THE USE OF RADIATION FOR STAGE I SEMINOMA: ANALYSIS OF THE NATIONAL CANCER DATABASE (2015) (0)
- Impact of number of cycles of platinum-based first-line chemotherapy for advanced urothelial carcinoma (2018) (0)
- Update on perioperative systemic therapy for urothelial carcinoma. (2019) (0)
- Efficacy of split schedule (SS) vs conventional schedule (CS) neoadjuvant cisplatin-based chemotherapy for muscle-invasive bladder cancer (MIBC). (2018) (0)
- Patients' Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19. (2023) (0)
- PI-10 DECLINING RATES OF RETROPERITONEAL LYMPH NODE DISSECTION FOR STAGE I NON-SEMINOMATOUS GERM CELL TUMORS: RESULTS FROM THE NATIONAL CANCER DATABASE (2015) (0)
- Perioperative pembrolizumab or pembrolizumab + enfortumab vedotin and cystectomy versus cystectomy alone in cisplatin-ineligible patients with muscle-invasive bladder cancer: Phase 3 KEYNOTE-905/EV-303 study (2021) (0)
- MP92-03 B-LYMPHOCYTES (BL) DIFFERENTIATION IS ATYPICAL IN CLEAR CELL RENAL CELL CARCINOMA (CCRCC) AND LOW PREOPERATIVE BL COUNT IS ASSOCIATED WITH POOR CANCER SPECIFIC SURVIVAL (CSS) (2016) (0)
- Abstract CT093: Axitinib in combination with pembrolizumab (AXI+PEMBRO) in patients (pts) with advanced renal cell carcinoma (aRCC): Analysis of immune-related biomarkers (2019) (0)
- Sporadic angiomyolipomas (AMLs) growth kinetics while on everolimus (SAGE). (2019) (0)
- MP41-04 URINARY CORRELATES OF PATHOLOGIC COMPLETE RESPONSE IN BLADDER CANCER PATIENTS RECEIVING NEOADJUVANT CHEMOTHERAPY (2018) (0)
- Chemoimmunotherapy in Metastatic Urothelial Carcinoma. (2018) (0)
- Abstract 6624: Immune correlates of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer (2020) (0)
- Safety and Efficacy of Nivolumab in PatientsWithMetastatic Renal Cell Carcinoma Treated Beyond Progression A Subgroup Analysis of a Randomized Clinical Trial (2016) (0)
- MP92-01 PD-1 EXPRESSION ON CLASSICAL MONOCYTES (CM) IS AN INDEPENDENT PREDICTOR OF CANCER SPECIFIC SURVIVAL IN CLEAR CELL RENAL CARCINOMA (CCRCC) (2016) (0)
- Rates of retroperitoneal lymph node dissection for stage I non-seminomatous germ cell tumors: Results from the National Cancer Database. (2015) (0)
- Bending the Curve of Advanced Urothelial Carcinoma. (2017) (0)
- Abstract SY05-03: Dissecting genomic correlates of response and resistance to chemotherapy in bladder cancer through clinical computational oncology (2019) (0)
- Abstract B29: Use of deep sequencing of urinary DNA as a biomarker of residual disease status at the time of radical cystectomy (2020) (0)
- Role of Gut Microbiome in Neoadjuvant Chemotherapy Response in Urothelial Carcinoma: A Multi-Institutional Prospective Cohort Evaluation (2023) (0)
- Germline genetic mutational landscape and characteristics of men with prostate cancer (PCa): A single institution experience. (2020) (0)
- Phase II randomized study of dalantercept in combination with axitinib compared to axitinib alone as second-line treatment in patients with metastatic renal cell carcinoma. (2013) (0)
- Novel early stopping rule uses early progression rather than lack of response as rapid assessment for futility. (2010) (0)
- Systemic Therapy for Advanced Bladder Cancer Evolves (2018) (0)
- 609 A Phase 1 Study of MEDI-573, an Investigational Monoclonal Antibody That Targets IGF-I and IGF-II: Safety, Pharmacokinetics, and Antitumor Activity in Adults with Advanced Solid Tumors (2012) (0)
- Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer (2017) (0)
- Reply by Authors. (2020) (0)
- Abstract 2918: Analysis of matched pre and post cisplatin-treated muscle-invasive bladder cancer reveals a candidate cisplatin mutational signature (2017) (0)
- Fox Chase Cancer Center's Genitourinary Division: a national resource for research, innovation and patient care. (2016) (0)
- Post hoc pooled analysis of first-line (1L) pembrolizumab (pembro) for advanced urothelial carcinoma (UC): Outcomes by response at week nine in KEYNOTE-052 and KEYNOTE-361. (2022) (0)
- Placing Adjuvant Chemotherapy in the Evolving Paradigm of Perioperative Therapy for Bladder Cancer. (2021) (0)
- Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B) (2023) (0)
- IMMUNE CORRELATES OF PATHOLOGIC RESPONSE IN BLADDER CANCER PATIENTS UNDERGOING NEOADJUVANT CHEMOTHERAPY: MP88‐11 (2017) (0)
- Analysis of an online tool to explore evolving practice patterns in renal cell carcinoma (RCC). (2018) (0)
- Post hoc analysis of the efficacy of pembrolizumab retreatment after progression of advanced urothelial carcinoma (UC) in KEYNOTE-045 and KEYNOTE-052. (2022) (0)
- Treatment of locally advanced or metastatic urothelial carcinoma: Analysis of expert and community healthcare provider practice trends. (2019) (0)
- A phase II trial of risk-enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN). (2023) (0)
- Elizabeth Plimack, MD, MS, Discusses Subsequent Therapy in Advanced RCC (2020) (0)
- Neoadjuvant cisplatin-based chemotherapy in patients with ureteral obstruction secondary to muscle invasive bladder cancer. (2020) (0)
- Issue Information (2022) (0)
- The prognostic significance of prenephrectomy absolute lymphocyte count in clear cell renal cell carcinoma. (2011) (0)
- The past, present, and future of pT0 in bladder cancer clinical trials (2022) (0)
- MP67-07 NEOADJUVANT CHEMOTHERAPY (NAC) HAS NO ADVERSE EFFECT ON RADICAL CYSTECTOMY (RC) OR PERIOPERATIVE COMPLICATIONS. (2015) (0)
- Osteoclast inhibitors in advanced prostate cancer: does the benefit extend beyond skeletal-related events? (2015) (0)
- Effect of cerebral dopamine metabolism genetic polymorphism on patient-reported quality-of-life (QOL): An analysis of the E3805 CHAARTED trial. (2023) (0)
- Safety and efficacy of neoadjuvant chemotherapy (NAC) with accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (aMVAC) in patients (pts) with muscle invasive bladder cancer (MIBC) as a function of age. (2020) (0)
- Optimizing Outcomes for Patients With Curable Bladder Cancer (2017) (0)
- Phase 1b/2 umbrella study of investigational immune and targeted combination therapies for patients with advanced clear cell renal cell carcinoma (ccRCC). (2022) (0)
- Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors. (2022) (0)
- Abstract 2188: Urothelial cancer-GENOmic analysis to improve patient outcomes and research (UC-GENOME): a bladder cancer advocacy network (BCAN) led collaborative research study (2021) (0)
- Abstract 3979: Immune correlates of pathologic response in bladder cancer patients undergoing neoadjuvant chemotherapy (2017) (0)
- Safety of neoadjuvant chemotherapy in patients with muscle‐invasive bladder cancer and malignant ureteric obstruction (2021) (0)
- PD50-07 SYSTEMATIC ENDOSCOPIC EVALUATION FALLS SHORT IN PREDICTING PT0 BLADDER CANCER (2020) (0)
- Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer. (2023) (0)
- Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A). (2023) (0)
- Bicalutamide with or without metformin for biochemical recurrence in prostate cancer patients (BIMET-1). (2020) (0)
- Abstract CT237: Interim results of a first-in-human phase 1 study of the oral MET kinase inhibitor, LY2801653, in patients with advanced cancer (2014) (0)
- Abstract CT243: A phase 1b/2 umbrella study of investigational immune and targeted combination therapies for patients with advanced renal cell carcinoma (RCC) who progressed on PD-1/L1 and VEGF inhibitors (2021) (0)
- Platinum-Free Systemic Therapy in First-Line Metastatic Urothelial Carcinoma: Mirage or Oasis in the Platinum Desert? (2022) (0)
- Author Correction: Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis (2021) (0)
- A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy. (2023) (0)
- Reply to S. Buti and S. Culine. (2013) (0)
- Treatment of metastatic recurrence of urothelial carcinoma after previous cisplatin-based chemotherapy: A retrospective comparison of different chemotherapy regimens. (2020) (0)
- Improved Outcomes in Men Treated With Adjuvant or Early Salvage Postprostatectomy IMRT or 3DCRT at a Single Institution (2013) (0)
- Pattern of relapse after perioperative chemotherapy and radical cystectomy versus radical cystectomy alone in patients with muscle-invasive bladder cancer (MIBC): A multicenter study (2017) (0)
- Identification of Groups at Increased Risk of Prostate Cancer (PCa) Death After Salvage Radiation Therapy (sRT) Using Recursive Partitioning Analysis (RPA): Results From an NCI-Designated Comprehensive Cancer Center (2014) (0)
- Abstract 5590: A phase I/II study of decitabine with pegylated interferon α-2b in advanced melanoma: clinical results and impact on DNA methylation and immune modulation (2012) (0)
- Neoadjuvant Chemotherapy with Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients with Muscle-invasive Bladder Cancer: A Retrospective Age-stratified Analysis on Safety and Efficacy. (2022) (0)
- Immune cell repertoire in patients with metastatic renal cell carcinoma: Data from prospective clinical trial. (2015) (0)
- A review of interventional clinical trials (CTs) in renal cell carcinoma (RCC): A status report from the ClinicalTrials.gov website. (2014) (0)
- Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye. (2014) (0)
- Metformin for biochemical recurrence of prostate cancer: Immune data from a phase 2 study. (2023) (0)
- Inflammatory Bowel Disease Is Not an Absolute Contraindication to Definitive Radiation Therapy for Prostate Cancer (2013) (0)
- Adding a Fourth Modality to Trimodal Therapy for Muscle-invasive Bladder Cancer. (2022) (0)
- Relapse-free survival (RFS) of clinical T2-4N0 urothelial bladder carcinoma (UBC) after radical cystectomy (RC), with or without perioperative chemotherapy (POC): Endpoints for clinical trial design. (2018) (0)
- Observational study of ifosfamide (Ifos) neurotoxicity (N): The prospective use of a nursing assessment tool. (2012) (0)
- PD03-11 TOLERABILITY AND ADVERSE EFFECT PROFILE OF EVEROLIMUS IN PATIENTS WITH SPORADIC ANGIOMYOLIPOMAS (2019) (0)
This paper list is powered by the following services:
Other Resources About Elizabeth Plimack
What Schools Are Affiliated With Elizabeth Plimack?
Elizabeth Plimack is affiliated with the following schools:
